ERBB2 and breast carcinoma: The luminal A outperformed the luminal B subtype in ER-positive breast cancers, while for ER-negative patients, the prognostic discrepancy between HER2-enriched and basal-like breast cancers were indistinguishable (Figures 5A and 6A).